News In Brief

Juno opens HQ & cancer research site

By Flora Southey

- Last updated on GMT

Juno Therapeutics has opened its new headquarters and research facility in South Lake Union, Seattle, US.

The development consolidates Juno’s Seattle team – previously spread across three locations – under one roof in South Lake Union.

The facility houses 65,000 sq. ft. of biosafety level one and two (BSL-1 & BSL-2) laboratory space over five floors. The focus will be the development of cell-based immunotherapies based on chimeric antigen, and high-affinity T cell receptors.

Spokesperson Chris Williams told us the site is strategically placed near Washington’s largest city.

“Our headquarters and research building is about 20 miles south of our manufacturing facility, which is located in Bothell, Washington, which his north of Seattle. The new HQ is in the same neighborhood as our previous HQ,”​ said Williams.

“For a variety of reasons, including attracting talent, we wanted to make sure our new building was in or near downtown Seattle,”​ he added.

Juno has premises across Washington, US, and Göttingen and Munich, Germany.

Related news

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...

Related suppliers